查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1715422

液態切片市場按生物標記、樣本、類型、技術、適應症、最終用戶和應用分類——2025-2030 年全球預測

Liquid Biopsy Market by Biomarkers, Sample, Type, Technology, Indication, End-User, Application - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計液態切片市場規模在 2023 年將達到 60 億美元，在 2024 年將成長至 67.2 億美元，在 2030 年將達到 134.4 億美元，複合年成長率為 12.19%。

主要市場統計數據
基準年2023年 60億美元
預計年份：2024年 67.2億美元
預測年份 2030 134.4億美元
複合年成長率（%） 12.19%

液態切片從根本上重新定義了診斷測試和個人化患者照護的領域。近年來，非侵入性診斷技術的創新正在徹底改變疾病（尤其是癌症）的檢測和監測方式。此方法依賴非固態生物組織（主要是血液）的採樣和分析，為傳統切片檢查提供了可行的替代方法。液態切片技術的發展源於其捕獲循環生物標記的能力，這些標誌物可提供有關疾病病理的即時資訊，並能夠及時、有針對性的治療性介入。

科學界對利用這項技術克服傳統組織切片檢查的局限性、增強早期檢測和促進持續監測的興趣日益濃厚。在研發投入不斷增加和精確分析工具整合的推動下，液態切片市場目前正處於臨床需求和技術進步的整合階段。除了在腫瘤學中的應用外，液態切片還迅速擴展到其他醫療保健領域，以提供更全面的診斷解決方案。該分析對當前市場狀況進行了深入研究，強調了趨勢、細分、區域見解和推動這場技術革命的主要企業。

液態切片格局的變化

受技術進步、法規結構不斷發展以及對微創診斷程序的需求不斷成長的推動，液態切片市場正在經歷快速轉型。在過去的幾年中，人們已經明顯地從傳統方法轉向提供更高精度、更快週轉時間和更廣泛適用性的解決方案。高效能定序、數據分析和自動化的進步不僅提高了測試結果的敏感度和特異性，而且使程式更具成本效益。

行業相關人員正在接受這些變化，尋求利用液態切片的能力來捕捉動態遺傳和表觀遺傳變化。這種變化體現在研究機構、技術提供者和醫療保健專業人員之間的積極合作，旨在改善生物標記的發現和檢驗過程。此外，簡化的監管途徑進一步加速了新工具和新檢測方法在臨床實踐中的引入。隨著市場採用率的擴大，競爭格局也不斷擴大，從而形成了一個持續創新和整合多領域專業知識至關重要的環境。液態切片的當前勢頭表明，採用精準醫療作為臨床診斷標準實踐的趨勢更為廣泛，最終有助於改善患者的治療效果並提高整個醫療保健系統的成本效率。

按市場細分的主要市場概況

對液態切片市場的詳細細分揭示了支持多種疾病檢測和管理方法的複雜結構。核心分析之一是基於生物標記，強調遊離DNA、循環性腫瘤細胞、循環腫瘤DNA和細胞外囊泡的重要性。這種基於生物標記的分割不僅突顯了多樣化的診斷能力，而且突顯了每種標記物提供的特定分子見解。按樣本類型細分同樣重要。該市場已透過多種利用血液和尿液樣本的方法進行了探索，既方便又有臨床效果。

此外，市場還根據所提供的產品或服務類型進行細分，包括檢測試劑套件、儀器和服務。同樣重要的是技術細分，依靠先進的平台，例如使用NGS進行多基因平行分析和使用PCR微陣列進行單基因分析。此細分進一步根據適應症區分應用，區分腫瘤學和非腫瘤學適應症。在癌症領域，子分類包括乳癌、結腸癌、肺癌、黑色素瘤和攝護腺癌等常見疾病，每種疾病都需要特定的診斷關注。另一個維度側重於最終用戶環境，從學術和研究中心到臨床診斷實驗室、醫院和醫生辦公室實驗室。最後，應用細分涵蓋早期癌症篩檢、復發監測、治療方法選擇和治療監測等過程，所有這些都支持全面的患者管理策略。

目錄

第1章 引言

第2章調查方法

第3章執行摘要

第4章 市場概述

第5章 市場洞察

  • 市場動態
    • 驅動程式
      • 全球癌症發生率不斷上升，需要早期診斷方法
      • 政府支持採用非侵入性診斷工具的措施和政策
    • 限制因素
      • 與循環性腫瘤細胞豐度低和脆弱性有關的擔憂
    • 機會
      • 資助液態切片領域的癌症研究擴展
      • 微陣列和次世代定序（NGS）的重要用途
    • 任務
      • 液態切片技術中的資料隱私問題和倫理問題
  • 市場區隔分析
    • 生物標記：cfDNA 在識別基因變異方面的多功能和重要用途
    • 例如：廣泛的臨床應用和強大的數據支持推動了血液液態生物檢體的使用增加
    • 類型：用於早期檢測和篩檢癌症症狀的檢測套組的使用演變
    • 技術：使用次世代定序 (NGS) 對多個基因進行平行分析越來越受到青睞，從而產生更高通量的數據
    • 適應症：由於乳癌發生率高，乳癌液態切片檢測的需求激增。
    • 最終用戶：液態切片檢測在臨床診斷實驗室中的使用量激增
    • 應用：液態切片在早期癌症篩檢中的應用呈指數級成長
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 經濟
    • 社會
    • 科技
    • 法律
    • 環境

第6章液態切片市場（按生物標記）

  • 介紹
  • 遊離DNA
  • 循環性腫瘤細胞
  • 循環腫瘤DNA
  • 細胞外囊泡

第7章液態切片市場（按樣本）

  • 介紹
  • 以血液為基礎
  • 尿基

第 8 章液態切片市場（按類型）

  • 介紹
  • 檢測試劑套件
  • 裝置
  • 服務

第9章液態切片市場（按技術）

  • 介紹
  • 使用NGS並行分析多個基因
  • 使用PCR微陣列進行單一基因分析

第 10 章液態切片市場（按適應症）

  • 介紹
  • 癌症適應症
    • 乳癌
    • 大腸直腸癌
    • 肺癌
    • 黑色素瘤
    • 攝護腺癌
  • 非癌症適應症

第 11 章液態切片市場（按最終用戶）

  • 介紹
  • 學術研究中心
  • 臨床診斷實驗室
  • 醫院
  • 醫生辦公室檢查室

第 12 章液態切片市場（按應用）

  • 介紹
  • 早期癌症篩檢
  • 復發監測
  • 治療方法方案
  • 治療監測

13.美洲液態切片市場

  • 介紹
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

14. 亞太液態切片市場

  • 介紹
  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

15. 歐洲、中東和非洲液態切片市場

  • 介紹
  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第16章競爭格局

  • 2023年市場佔有率分析
  • 2023年FPNV定位矩陣
  • 競爭情境分析
  • 戰略分析與建議

公司名單

  • ANGLE PLC
  • Bio-Rad Laboratories, Inc.
  • Bio-Techne Corporation
  • Biocartis NV
  • Danaher Corporation
  • DiaCarta, Inc.
  • Dxcover Limited
  • Epic Sciences Inc.
  • Exact Sciences Corporation
  • F. Hoffmann-La Roche Ltd.
  • GENCURIX
  • Guardant Health, Inc.
  • Illumina, Inc.
  • Labcorp Holdings Inc.
  • Laboratory Dr. med. Pachmann
  • Lucence Health Inc.
  • LungLife AI, Inc.
  • MDxHealth SA
  • Menarini Silicon Biosystems SpA
  • Merck KGaA
  • Myriad Genetics, Inc.
  • Natera, Inc.
  • NeoGenomics Laboratories, Inc.
  • OncoDNA SA
  • PerkinElmer, Inc.
  • Personalis, Inc.
  • QIAGEN NV
  • SAGA Diagnostics AB
  • Strand Life Sciences Pvt Ltd.
  • Sysmex Corporation
  • Tempus AI, Inc.
  • Thermo Fisher Scientific Inc.
Product Code: MRR-43470FC608C8

The Liquid Biopsy Market was valued at USD 6.00 billion in 2023 and is projected to grow to USD 6.72 billion in 2024, with a CAGR of 12.19%, reaching USD 13.44 billion by 2030.

KEY MARKET STATISTICS
Base Year [2023] USD 6.00 billion
Estimated Year [2024] USD 6.72 billion
Forecast Year [2030] USD 13.44 billion
CAGR (%) 12.19%

Liquid biopsy has fundamentally redefined the landscape of diagnostic testing and personalized patient care. Over recent years, innovations in non-invasive diagnostics have set the stage for transformative change in how diseases, particularly cancer, are detected and monitored. This method, which relies on sampling and analyzing non-solid biological tissue, primarily blood, offers a viable alternative to traditional surgical biopsies. The evolution of liquid biopsy technology is driven by its ability to capture circulating biomarkers that provide real-time information about the disease state, enabling timely and targeted therapeutic interventions.

The scientific community has shown an increasing interest in leveraging this technique to overcome the limitations of conventional tissue biopsy, enhancing early detection and facilitating ongoing monitoring. With growing investment in research and development and the integration of high-precision analytical tools, the liquid biopsy market now stands at the convergence of clinical need and technological advancement. In addition to its applications in oncology, liquid biopsy is rapidly expanding its footprint into other areas of medicine, enabling more comprehensive diagnostic solutions. This analysis provides an in-depth look into the current state of the market, elucidating the trends, segmentation, regional insights, and major players who are driving this innovation forward.

Transformative Shifts in the Landscape of Liquid Biopsy

The liquid biopsy market is witnessing rapid transformation fueled by advancements in technology, evolving regulatory frameworks, and increasing demand for minimally invasive diagnostic procedures. Over the past few years, there has been a distinct shift away from traditional methods towards solutions that offer greater precision, faster turnaround times, and broader applicability. Improvements in high-throughput sequencing, data analytics, and automation have not only enhanced the sensitivity and specificity of test results but also made the procedures more cost-effective.

Industry stakeholders are embracing these changes as they seek to leverage the ability of liquid biopsies to capture dynamic genetic and epigenetic alterations. This shift is marked by proactive collaborations between research institutions, technology providers, and healthcare practitioners aimed at refining biomarker discovery and validation processes. Moreover, streamlined regulatory pathways have further accelerated the introduction of novel tools and assays into the clinical setting. As market adoption expands, so too does the competitive landscape, leading to an environment where continuous innovation and integration of multi-disciplinary expertise remain essential. The current momentum surrounding liquid biopsy illustrates a broader trend of adopting precision medicine as a standard practice in clinical diagnostics, ultimately contributing to improved patient outcomes and cost efficiencies across healthcare systems.

Key Segmentation Insights for a Nuanced Market Overview

A detailed segmentation of the liquid biopsy market reveals an intricate structure that supports a diversified approach to disease detection and management. One of the core dimensions of the analysis is based on biomarkers, which underscores the importance of Cell-free DNA, Circulating Tumor Cells, Circulating Tumor DNA, and Extracellular Vesicles. This biomarker-based segmentation not only highlights the varied diagnostic capabilities but also emphasizes the specific molecular insights that each marker provides. Equally important is the segmentation based on sample type. The market is studied across methodologies that utilize Blood Based and Urine Based samples, supporting both convenience and clinical effectiveness.

Furthermore, the market is categorized by the type of products and services offered, encompassing Assay Kits, Instruments, and Services, each playing a unique role in driving diagnostic performance. Equally significant is the segmentation based on technology, which leans on advanced platforms such as Multi-gene Parallel Analysis using NGS and Single-gene Analysis using PCR Microarrays. The segmentation further differentiates applications by indication, distinguishing between Cancer Indication and Non-Cancer Indication. In the cancer segment, sub-classifications include prevalent conditions such as Breast Cancer, Colorectal Cancer, Lung Cancer, Melanoma, and Prostate Cancer, each requiring specific diagnostic attention. Other dimensions focus on end-user environments, ranging from Academic & Research Centers to Clinical Diagnostic Laboratories, Hospitals, and Physician's Office Laboratories. Finally, the application segmentation covers processes such as Early Cancer Screening, Recurrence Monitoring, Therapy Selection, and Treatment Monitoring, all of which collectively underpin a comprehensive patient management strategy.

Based on Biomarkers, market is studied across Cell-free DNA, Circulating Tumor Cells, Circulating Tumor DNA, and Extracellular Vesicles.

Based on Sample, market is studied across Blood Based and Urine Based.

Based on Type, market is studied across Assay Kits, Instruments, and Services.

Based on Technology, market is studied across Multi-gene Parallel Analysis using NGS and Single-gene Analysis using PCR Microarrays.

Based on Indication, market is studied across Cancer Indication and Non-Cancer Indication. The Cancer Indication is further studied across Breast Cancer, Colorectal Cancer, Lung Cancer, Melanoma, and Prostate Cancer.

Based on End-User, market is studied across Academic & Research Centers, Clinical Diagnostic Laboratories, Hospitals, and Physician's Office Laboratories.

Based on Application, market is studied across Early Cancer Screening, Recurrence Monitoring, Therapy Selection, and Treatment Monitoring.

Key Regional Insights Shaping Market Dynamics

Geographical analysis reveals distinctive growth patterns and market dynamics across different regions. In the Americas, high healthcare expenditure and advanced technological adoption in diagnostic practices have fostered rapid market growth and innovation. The region has been instrumental in validating cutting-edge approaches to liquid biopsy, driven by a synergistic ecosystem of research institutions, biotech companies, and regulatory support.

In the combined region of Europe, Middle East & Africa, the market benefits from robust public healthcare systems and collaborative research efforts that bridge technology with clinical practice. Firms in these regions are increasingly investing in the development of assays and platforms tailored to local healthcare needs, thereby enhancing diagnostic access and efficacy. Asia-Pacific stands out as a key growth driver, with emerging economies spearheading investment in healthcare infrastructure and diagnostic technologies. Government initiatives and rapidly expanding insurance coverage are further catalyzing market expansion. Cultural shifts towards early disease detection, combined with increased awareness and adoption of preventive healthcare measures, are expected to propel this region into a leading market segment over the coming years. Such geographical diversity highlights the regional nuances that collectively contribute to the global narrative of the liquid biopsy revolution.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Key Companies Steering Innovation and Competition

The competitive landscape in the liquid biopsy market is characterized by a blend of established industry giants and nimble innovators. Prominent market players such as ANGLE PLC, Bio-Rad Laboratories, Inc., and Bio-Techne Corporation have cemented their roles by continuously investing in new technologies and expanding their product portfolios. Biocartis NV and Danaher Corporation, along with DiaCarta, Inc. and Dxcover Limited, are also pivotal in driving forward the diagnostic capabilities of liquid biopsy through strategic collaborations and cutting-edge research.

Epic Sciences Inc. and Exact Sciences Corporation have distinguished themselves by developing assays that offer high sensitivity and specificity, thereby setting benchmarks for clinical outcomes. F. Hoffmann-La Roche Ltd. and GENCURIX have leveraged their extensive experience in diagnostics to integrate liquid biopsy into broader therapeutic management frameworks. Companies such as Guardant Health, Inc. and Illumina, Inc. are renowned for their state-of-the-art sequencing technologies, which have significantly advanced the liquid biopsy field. The market is further enriched by contributions from Labcorp Holdings Inc., Laboratory Dr. med. Pachmann, and Lucence Health Inc., whose innovative solutions drive process improvements in sample analysis. LungLife AI, Inc. and MDxHealth SA are actively involved in the development of artificial intelligence tools that further enhance diagnostic precision, while players like Menarini Silicon Biosystems SpA, Merck KGaA, and Myriad Genetics, Inc. maintain strong research pipelines. Natera, Inc., NeoGenomics Laboratories, Inc., OncoDNA SA, PerkinElmer, Inc., Personalis, Inc., QIAGEN N.V., SAGA Diagnostics AB, Strand Life Sciences Pvt Ltd., Sysmex Corporation, Tempus AI, Inc., and Thermo Fisher Scientific Inc. round out the competitive spectrum by contributing critical research, robust analytical frameworks, and dynamic market strategies that collectively propel the industry toward sustained innovation and global influence.

The report delves into recent significant developments in the Liquid Biopsy Market, highlighting leading vendors and their innovative profiles. These include ANGLE PLC, Bio-Rad Laboratories, Inc., Bio-Techne Corporation, Biocartis NV, Danaher Corporation, DiaCarta, Inc., Dxcover Limited, Epic Sciences Inc., Exact Sciences Corporation, F. Hoffmann-La Roche Ltd., GENCURIX, Guardant Health, Inc., Illumina, Inc., Labcorp Holdings Inc., Laboratory Dr. med. Pachmann, Lucence Health Inc., LungLife AI, Inc., MDxHealth SA, Menarini Silicon Biosystems SpA, Merck KGaA, Myriad Genetics, Inc., Natera, Inc., NeoGenomics Laboratories, Inc., OncoDNA SA, PerkinElmer, Inc., Personalis, Inc., QIAGEN N.V., SAGA Diagnostics AB, Strand Life Sciences Pvt Ltd., Sysmex Corporation, Tempus AI, Inc., and Thermo Fisher Scientific Inc.. Actionable Recommendations for Industry Leaders

Industry leaders are advised to invest in furthering diagnostic research and technological innovation while integrating cross-functional collaboration with clinical practitioners to boost validation studies. Active engagement in strategic partnerships with both academia and technology developers will ensure that emerging trends and regulatory changes are effectively leveraged to maintain competitive advantage. Emphasis should be placed on diversifying product suites to include next-generation sequencing platforms and advanced amplification tools that cater to evolving market needs. Furthermore, leaders must continuously evaluate supply chain efficiencies and streamline operational processes to reduce time-to-market for new diagnostic tools. Adoption of digital analytics and data management solutions can also play a pivotal role in optimizing clinical decision-making and improving patient outcomes. By staying abreast of technological advancements and regional market trends, companies can secure a leading position in a rapidly evolving landscape.

Conclusion: Charting the Course for Future Success

In summary, the liquid biopsy market represents a dynamic intersection of technological innovation and clinical application. The comprehensive insights provided, categorized by biomarkers, sample types, product offerings, technologies, indications, end-user environments, and applications, underscore the evolving nature of diagnostics in the modern medical landscape. Regional and competitive analyses further highlight that success in this arena depends on the ability to integrate cutting-edge science with strategic execution. As the market continues to mature, ongoing innovation and adaptive strategies will be crucial in meeting the challenges of evolving disease profiles and regulatory environments. This analysis reaffirms that a proactive, research-driven approach remains central to leveraging the full potential of liquid biopsy applications.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of cancer worldwide necessitating early diagnosis methods
      • 5.1.1.2. Supportive government initiatives and policies for the adoption of non-invasive diagnostic tools
    • 5.1.2. Restraints
      • 5.1.2.1. Concerns associated with low abundance and fragile nature of the circulating tumor cells
    • 5.1.3. Opportunities
      • 5.1.3.1. Availability of funding to expand cancer research in the field of liquid biopsy
      • 5.1.3.2. Significant use of microarrays and next-generation sequencing (NGS)
    • 5.1.4. Challenges
      • 5.1.4.1. Data privacy concerns and ethical issues in liquid biopsy technology
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Biomarkers: Significant utilization of cell-free DNA (cfDNA) versatile in identifying genetic changes
    • 5.2.2. Sample: Rising usage of blood-based liquid biopsies owing to their broad clinical applications and robust data support
    • 5.2.3. Type: Evolving usage of assay kits for early detection and screening of cancer symptoms
    • 5.2.4. Technology: Increasing preference for the multi-gene parallel analysis using next-generation sequencing (NGS), offering higher throughput data
    • 5.2.5. Indication: Burgeoning preference for liquid biopsy tests for breast cancer due to its high prevalence
    • 5.2.6. End-User: Proliferating usage of the liquid biopsy test across the clinical diagnostic laboratories
    • 5.2.7. Application: Exponential utilization of the liquid biopsy for early cancer screening
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Liquid Biopsy Market, by Biomarkers

  • 6.1. Introduction
  • 6.2. Cell-free DNA
  • 6.3. Circulating Tumor Cells
  • 6.4. Circulating Tumor DNA
  • 6.5. Extracellular Vesicles

7. Liquid Biopsy Market, by Sample

  • 7.1. Introduction
  • 7.2. Blood Based
  • 7.3. Urine Based

8. Liquid Biopsy Market, by Type

  • 8.1. Introduction
  • 8.2. Assay Kits
  • 8.3. Instruments
  • 8.4. Services

9. Liquid Biopsy Market, by Technology

  • 9.1. Introduction
  • 9.2. Multi-gene Parallel Analysis using NGS
  • 9.3. Single-gene Analysis using PCR Microarrays

10. Liquid Biopsy Market, by Indication

  • 10.1. Introduction
  • 10.2. Cancer Indication
    • 10.2.1. Breast Cancer
    • 10.2.2. Colorectal Cancer
    • 10.2.3. Lung Cancer
    • 10.2.4. Melanoma
    • 10.2.5. Prostate Cancer
  • 10.3. Non-Cancer Indication

11. Liquid Biopsy Market, by End-User

  • 11.1. Introduction
  • 11.2. Academic & Research Centers
  • 11.3. Clinical Diagnostic Laboratories
  • 11.4. Hospitals
  • 11.5. Physician's Office Laboratories

12. Liquid Biopsy Market, by Application

  • 12.1. Introduction
  • 12.2. Early Cancer Screening
  • 12.3. Recurrence Monitoring
  • 12.4. Therapy Selection
  • 12.5. Treatment Monitoring

13. Americas Liquid Biopsy Market

  • 13.1. Introduction
  • 13.2. Argentina
  • 13.3. Brazil
  • 13.4. Canada
  • 13.5. Mexico
  • 13.6. United States

14. Asia-Pacific Liquid Biopsy Market

  • 14.1. Introduction
  • 14.2. Australia
  • 14.3. China
  • 14.4. India
  • 14.5. Indonesia
  • 14.6. Japan
  • 14.7. Malaysia
  • 14.8. Philippines
  • 14.9. Singapore
  • 14.10. South Korea
  • 14.11. Taiwan
  • 14.12. Thailand
  • 14.13. Vietnam

15. Europe, Middle East & Africa Liquid Biopsy Market

  • 15.1. Introduction
  • 15.2. Denmark
  • 15.3. Egypt
  • 15.4. Finland
  • 15.5. France
  • 15.6. Germany
  • 15.7. Israel
  • 15.8. Italy
  • 15.9. Netherlands
  • 15.10. Nigeria
  • 15.11. Norway
  • 15.12. Poland
  • 15.13. Qatar
  • 15.14. Russia
  • 15.15. Saudi Arabia
  • 15.16. South Africa
  • 15.17. Spain
  • 15.18. Sweden
  • 15.19. Switzerland
  • 15.20. Turkey
  • 15.21. United Arab Emirates
  • 15.22. United Kingdom

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2023
  • 16.2. FPNV Positioning Matrix, 2023
  • 16.3. Competitive Scenario Analysis
    • 16.3.1. Mayo Clinic and Lucence join forces to expand global liquid biopsy access
    • 16.3.2. PanGIA Biotech and Canary Oncoceutics partner to pioneer an AI-integrated urine-based liquid biopsy
    • 16.3.3. QIAGEN expands liquid biopsy automation portfolio
    • 16.3.4. Strand Life Sciences launches liquid biopsy test for improved cancer diagnosis
    • 16.3.5. Novigenix unveils an AI-powered multimodal liquid biopsy approach that integrates cfDNA analysis and mRNA immune profiling
    • 16.3.6. SOPHiA GENETICS partners with the European Liquid Biopsy Society to advance decentralized liquid biopsy solutions
    • 16.3.7. Hitachi High-Tech and Gencurix forge strategic partnership to revolutionize cancer molecular diagnostics through advanced liquid biopsy and digital reporting for personalized treatment decisions
    • 16.3.8. Personalis and Tempus partner to advance precision liquid biopsy diagnostics
    • 16.3.9. Renovaro Biosciences to acquire Cyclomics to transform liquid biopsy technology
    • 16.3.10. Myriad Genetics expands its oncology portfolio by acquiring Precise Tumor and Precise Liquid assays from Intermountain Precision Genomics
    • 16.3.11. Veracyte strengthens liquid biopsy platform with C2i Genomics acquisition
  • 16.4. Strategy Analysis & Recommendation
    • 16.4.1. F. Hoffmann-La Roche Ltd.
    • 16.4.2. Illumina, Inc.
    • 16.4.3. QIAGEN N.V.
    • 16.4.4. Guardant Health, Inc.

Companies Mentioned

  • 1. ANGLE PLC
  • 2. Bio-Rad Laboratories, Inc.
  • 3. Bio-Techne Corporation
  • 4. Biocartis NV
  • 5. Danaher Corporation
  • 6. DiaCarta, Inc.
  • 7. Dxcover Limited
  • 8. Epic Sciences Inc.
  • 9. Exact Sciences Corporation
  • 10. F. Hoffmann-La Roche Ltd.
  • 11. GENCURIX
  • 12. Guardant Health, Inc.
  • 13. Illumina, Inc.
  • 14. Labcorp Holdings Inc.
  • 15. Laboratory Dr. med. Pachmann
  • 16. Lucence Health Inc.
  • 17. LungLife AI, Inc.
  • 18. MDxHealth SA
  • 19. Menarini Silicon Biosystems SpA
  • 20. Merck KGaA
  • 21. Myriad Genetics, Inc.
  • 22. Natera, Inc.
  • 23. NeoGenomics Laboratories, Inc.
  • 24. OncoDNA SA
  • 25. PerkinElmer, Inc.
  • 26. Personalis, Inc.
  • 27. QIAGEN N.V.
  • 28. SAGA Diagnostics AB
  • 29. Strand Life Sciences Pvt Ltd.
  • 30. Sysmex Corporation
  • 31. Tempus AI, Inc.
  • 32. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. LIQUID BIOPSY MARKET MULTI-CURRENCY
  • FIGURE 2. LIQUID BIOPSY MARKET MULTI-LANGUAGE
  • FIGURE 3. LIQUID BIOPSY MARKET RESEARCH PROCESS
  • FIGURE 4. LIQUID BIOPSY MARKET SIZE, 2023 VS 2030
  • FIGURE 5. GLOBAL LIQUID BIOPSY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL LIQUID BIOPSY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL LIQUID BIOPSY MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL LIQUID BIOPSY MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 17. GLOBAL LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. GLOBAL LIQUID BIOPSY MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 19. GLOBAL LIQUID BIOPSY MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. GLOBAL LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 21. GLOBAL LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. AMERICAS LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. AMERICAS LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. UNITED STATES LIQUID BIOPSY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 25. UNITED STATES LIQUID BIOPSY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 26. ASIA-PACIFIC LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 27. ASIA-PACIFIC LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 28. EUROPE, MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 29. EUROPE, MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 30. LIQUID BIOPSY MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 31. LIQUID BIOPSY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. LIQUID BIOPSY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL LIQUID BIOPSY MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL LIQUID BIOPSY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. LIQUID BIOPSY MARKET DYNAMICS
  • TABLE 7. GLOBAL LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL LIQUID BIOPSY MARKET SIZE, BY CELL-FREE DNA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL LIQUID BIOPSY MARKET SIZE, BY CIRCULATING TUMOR CELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL LIQUID BIOPSY MARKET SIZE, BY CIRCULATING TUMOR DNA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL LIQUID BIOPSY MARKET SIZE, BY EXTRACELLULAR VESICLES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL LIQUID BIOPSY MARKET SIZE, BY BLOOD BASED, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL LIQUID BIOPSY MARKET SIZE, BY URINE BASED, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL LIQUID BIOPSY MARKET SIZE, BY ASSAY KITS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL LIQUID BIOPSY MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL LIQUID BIOPSY MARKET SIZE, BY SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL LIQUID BIOPSY MARKET SIZE, BY MULTI-GENE PARALLEL ANALYSIS USING NGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL LIQUID BIOPSY MARKET SIZE, BY SINGLE-GENE ANALYSIS USING PCR MICROARRAYS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL LIQUID BIOPSY MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL LIQUID BIOPSY MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL LIQUID BIOPSY MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL LIQUID BIOPSY MARKET SIZE, BY MELANOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL LIQUID BIOPSY MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL LIQUID BIOPSY MARKET SIZE, BY NON-CANCER INDICATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL LIQUID BIOPSY MARKET SIZE, BY ACADEMIC & RESEARCH CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL LIQUID BIOPSY MARKET SIZE, BY CLINICAL DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL LIQUID BIOPSY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL LIQUID BIOPSY MARKET SIZE, BY PHYSICIAN'S OFFICE LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL LIQUID BIOPSY MARKET SIZE, BY EARLY CANCER SCREENING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL LIQUID BIOPSY MARKET SIZE, BY RECURRENCE MONITORING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL LIQUID BIOPSY MARKET SIZE, BY THERAPY SELECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL LIQUID BIOPSY MARKET SIZE, BY TREATMENT MONITORING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 42. AMERICAS LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 43. AMERICAS LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. AMERICAS LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 45. AMERICAS LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 46. AMERICAS LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 47. AMERICAS LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 48. AMERICAS LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 49. AMERICAS LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 50. ARGENTINA LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 51. ARGENTINA LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 52. ARGENTINA LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. ARGENTINA LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 54. ARGENTINA LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 55. ARGENTINA LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 56. ARGENTINA LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 57. ARGENTINA LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 58. BRAZIL LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 59. BRAZIL LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 60. BRAZIL LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. BRAZIL LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 62. BRAZIL LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 63. BRAZIL LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 64. BRAZIL LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 65. BRAZIL LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 66. CANADA LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 67. CANADA LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 68. CANADA LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. CANADA LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 70. CANADA LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 71. CANADA LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 72. CANADA LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 73. CANADA LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 74. MEXICO LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 75. MEXICO LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 76. MEXICO LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. MEXICO LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 78. MEXICO LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 79. MEXICO LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 80. MEXICO LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 81. MEXICO LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 82. UNITED STATES LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 83. UNITED STATES LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 84. UNITED STATES LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. UNITED STATES LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 86. UNITED STATES LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 87. UNITED STATES LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 88. UNITED STATES LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 89. UNITED STATES LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 90. UNITED STATES LIQUID BIOPSY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 100. AUSTRALIA LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 101. AUSTRALIA LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 102. AUSTRALIA LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. AUSTRALIA LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 104. AUSTRALIA LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 105. AUSTRALIA LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 106. AUSTRALIA LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 107. AUSTRALIA LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 108. CHINA LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 109. CHINA LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 110. CHINA LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. CHINA LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 112. CHINA LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 113. CHINA LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 114. CHINA LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 115. CHINA LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 116. INDIA LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 117. INDIA LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 118. INDIA LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. INDIA LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 120. INDIA LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 121. INDIA LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 122. INDIA LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 123. INDIA LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 124. INDONESIA LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 125. INDONESIA LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 126. INDONESIA LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. INDONESIA LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 128. INDONESIA LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 129. INDONESIA LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 130. INDONESIA LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 131. INDONESIA LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 132. JAPAN LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 133. JAPAN LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 134. JAPAN LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. JAPAN LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 136. JAPAN LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 137. JAPAN LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 138. JAPAN LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 139. JAPAN LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 140. MALAYSIA LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 141. MALAYSIA LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 142. MALAYSIA LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. MALAYSIA LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 144. MALAYSIA LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 145. MALAYSIA LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 146. MALAYSIA LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 147. MALAYSIA LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 148. PHILIPPINES LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 149. PHILIPPINES LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 150. PHILIPPINES LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. PHILIPPINES LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 152. PHILIPPINES LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 153. PHILIPPINES LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 154. PHILIPPINES LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 155. PHILIPPINES LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 156. SINGAPORE LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 157. SINGAPORE LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 158. SINGAPORE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. SINGAPORE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 160. SINGAPORE LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 161. SINGAPORE LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 162. SINGAPORE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 163. SINGAPORE LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH KOREA LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH KOREA LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH KOREA LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH KOREA LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 168. SOUTH KOREA LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 169. SOUTH KOREA LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 170. SOUTH KOREA LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 171. SOUTH KOREA LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 172. TAIWAN LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 173. TAIWAN LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 174. TAIWAN LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. TAIWAN LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 176. TAIWAN LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 177. TAIWAN LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 178. TAIWAN LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 179. TAIWAN LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 180. THAILAND LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 181. THAILAND LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 182. THAILAND LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. THAILAND LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 184. THAILAND LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 185. THAILAND LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 186. THAILAND LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 187. THAILAND LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 188. VIETNAM LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 189. VIETNAM LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 190. VIETNAM LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 191. VIETNAM LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 192. VIETNAM LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 193. VIETNAM LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 194. VIETNAM LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 195. VIETNAM LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 205. DENMARK LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 206. DENMARK LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 207. DENMARK LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 208. DENMARK LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 209. DENMARK LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 210. DENMARK LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 211. DENMARK LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 212. DENMARK LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 213. EGYPT LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 214. EGYPT LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 215. EGYPT LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 216. EGYPT LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 217. EGYPT LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 218. EGYPT LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 219. EGYPT LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 220. EGYPT LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 221. FINLAND LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 222. FINLAND LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 223. FINLAND LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 224. FINLAND LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 225. FINLAND LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 226. FINLAND LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 227. FINLAND LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 228. FINLAND LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 229. FRANCE LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 230. FRANCE LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 231. FRANCE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 232. FRANCE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 233. FRANCE LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 234. FRANCE LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 235. FRANCE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 236. FRANCE LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 237. GERMANY LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 238. GERMANY LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 239. GERMANY LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 240. GERMANY LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 241. GERMANY LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 242. GERMANY LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 243. GERMANY LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 244. GERMANY LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 245. ISRAEL LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 246. ISRAEL LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 247. ISRAEL LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 248. ISRAEL LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 249. ISRAEL LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 250. ISRAEL LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 251. ISRAEL LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 252. ISRAEL LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 253. ITALY LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 254. ITALY LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 255. ITALY LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 256. ITALY LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 257. ITALY LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 258. ITALY LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 259. ITALY LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 260. ITALY LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 261. NETHERLANDS LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 262. NETHERLANDS LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 263. NETHERLANDS LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 264. NETHERLANDS LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 265. NETHERLANDS LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 266. NETHERLANDS LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 267. NETHERLANDS LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 268. NETHERLANDS LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 269. NIGERIA LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 270. NIGERIA LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 271. NIGERIA LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 272. NIGERIA LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 273. NIGERIA LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 274. NIGERIA LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 275. NIGERIA LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 276. NIGERIA LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 277. NORWAY LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 278. NORWAY LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 279. NORWAY LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 280. NORWAY LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 281. NORWAY LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 282. NORWAY LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 283. NORWAY LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 284. NORWAY LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 285. POLAND LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 286. POLAND LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 287. POLAND LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 288. POLAND LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 289. POLAND LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 290. POLAND LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 291. POLAND LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 292. POLAND LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 293. QATAR LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 294. QATAR LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 295. QATAR LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 296. QATAR LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 297. QATAR LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 298. QATAR LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 299. QATAR LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 300. QATAR LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 301. RUSSIA LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 302. RUSSIA LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 303. RUSSIA LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 304. RUSSIA LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 305. RUSSIA LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 306. RUSSIA LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 307. RUSSIA LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 308. RUSSIA LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 309. SAUDI ARABIA LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 310. SAUDI ARABIA LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 311. SAUDI ARABIA LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 312. SAUDI ARABIA LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 313. SAUDI ARABIA LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 314. SAUDI ARABIA LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 315. SAUDI ARABIA LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 316. SAUDI ARABIA LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 317. SOUTH AFRICA LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 318. SOUTH AFRICA LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 319. SOUTH AFRICA LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 320. SOUTH AFRICA LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 321. SOUTH AFRICA LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 322. SOUTH AFRICA LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 323. SOUTH AFRICA LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 324. SOUTH AFRICA LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 325. SPAIN LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 326. SPAIN LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 327. SPAIN LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 328. SPAIN LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 329. SPAIN LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 330. SPAIN LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 331. SPAIN LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 332. SPAIN LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 333. SWEDEN LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 334. SWEDEN LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 335. SWEDEN LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 336. SWEDEN LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 337. SWEDEN LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 338. SWEDEN LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 339. SWEDEN LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 340. SWEDEN LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 341. SWITZERLAND LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 342. SWITZERLAND LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 343. SWITZERLAND LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 344. SWITZERLAND LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 345. SWITZERLAND LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 346. SWITZERLAND LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 347. SWITZERLAND LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 348. SWITZERLAND LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 349. TURKEY LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 350. TURKEY LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 351. TURKEY LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 352. TURKEY LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 353. TURKEY LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 354. TURKEY LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 355. TURKEY LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 356. TURKEY LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 357. UNITED ARAB EMIRATES LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 358. UNITED ARAB EMIRATES LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 359. UNITED ARAB EMIRATES LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 360. UNITED ARAB EMIRATES LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 361. UNITED ARAB EMIRATES LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 362. UNITED ARAB EMIRATES LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 363. UNITED ARAB EMIRATES LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 364. UNITED ARAB EMIRATES LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 365. UNITED KINGDOM LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 366. UNITED KINGDOM LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 367. UNITED KINGDOM LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 368. UNITED KINGDOM LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 369. UNITED KINGDOM LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 370. UNITED KINGDOM LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
  • TABLE 371. UNITED KINGDOM LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 372. UNITED KINGDOM LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 373. LIQUID BIOPSY MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 374. LIQUID BIOPSY MARKET, FPNV POSITIONING MATRIX, 2023